Numerous signalling pathways in cells are influenced by the ubiquitous Ser/Thr protein kinase CK2. Protein kinase CK2 is composed of two regulatory b-subunits and two catalytic a-or a 0 -subunits. Several of the known CK2 substrates are proteins known to regulate transcriptional events. Here, we describe that protein kinase CK2 interacts with the splicing factor hPrp3p, which is important for the assembly of the spliceosome. In a twohybrid screen hPrp3p is exclusively bound to the catalytic a-or a 0 -subunits of CK2 but not to the regulatory bsubunit. The interaction was confirmed by coimmunoprecipitation experiments in vitro and in vivo. Moreover, both proteins colocalized in nuclear speckles which is typical for splicing factor compartments within the nucleus. Phosphorylation experiments revealed that hPrp3p is also a substrate of protein kinase CK2. The main phosphorylation site was mapped to C-terminal residues. In vitro and in vivo splicing assays showed that the splicing activity is significantly influenced by the CK2-hPrp3p interaction. Thus, these data showed that CK2 is involved in the regulation of RNA processing.
Introduction
More than 40 years ago Burnett and Kennedy isolated a phosphotransferase from liver extracts which did not fit into the scheme of all other kinases found to that date (Burnett and Kennedy, 1954) . It is a heterotetrameric enzyme consisting of two catalytic a-or a 0 -and two regulatory b-subunits which prefers serine or threonine residues within acidic consensus sequences as targets, and which can use both, guanosine 5 0 -triphosphate (GTP) and adenosine 5 0 -triphosphate (ATP) as phosphate donors. Both, CK2 and CK1 prefer to phosphorylate acidophilic targets, but they belong to different groups of kinases. CK2 belongs to the CMCG group whereas CK1 belongs to the OPK XII group. A peculiar feature of CK2 is that it not only acts as a phosphotransferase but that it can also influence the biological activity of some proteins, like topoisomerase I, by pure interaction (Pinna, 2002; Litchfield, 2003) . Furthermore, there is ample evidence that CK2 not only appears as a tetrameric holoenzyme in the cell but also as individual subunits. Free a-as well as free b-subunits have been found in the cell provided with important individual functions (Stalter et al., 1994; Guerra et al., 1999) .
Protein kinase CK2 is a highly conserved enzyme. It has been found in a wide variety of organisms from yeast to man and in all cells and tissues with a different expression level. Although its true function is not yet known, life without CK2 is not possible. These observations together with the fact that CK2 activity is enhanced in proliferating cells, underline the importance of CK2 for cell growth. Among the more than 300 substrates discovered to this date, are a lot of proteins that are implicated in cell cycle control, DNA replication/repair, proliferation and transcription/translation (Meggio and Pinna, 2003) . The C-terminal domain (CTD) of the largest RNA polymerase II subunit (Cabrejos et al., 2004) , the TFIIF-dependent CTD phosphatase 1 (FCP1) (Palancade et al., 2002) and cyclin H (Faust et al., 2002; Schneider et al., 2002; Krempler et al., 2005) belong to the substrates that are known to regulate transcriptional events. Cyclin H is phosphorylated at threonine 315 by CK2 and this phosphorylation is needed for full activity of the cdk7/ cyclin H/Mat1 complex towards a CTD peptide of RNA polymerase II. The phosphorylation of the CTD is necessary for the switch of the initiation to the elongation step of transcription. CK2 is also directly involved in the splicing process as it phosphorylates RNPS1, which is a splicing regulator whose activator function is, at least in part, controlled by CK2 phosphorylation (Trembley et al., 2005) .
hPrp3p is a human pre-mRNA splicing factor that, in a mutant form, leads to autosomal dominant Retinitis pigmentosa (Chakarova et al., 2002) . hPrp3p presumably plays an important role in recruiting other splicing factors like hPrp4p to the U4/U6 small ribonucleoprotein and docking the U4/U6/U5 tri-snRNP to the prespliceosome (Liu et al., 2006) . In the present study we describe that hPrp3p interacts with protein kinase CK2 in vitro and in vivo and that is phosphorylated by this kinase. The catalytic subunits of CK2 are colocalized with hPrp3p in nuclear speckles during the gap phases of the cell cycle. Furthermore, the splicing activity of the spliceosome is influenced by protein kinase CK2.
Results
The catalytic subunits of protein kinase CK2 interact with the splicing factor hPrp3p By performing a two-hybrid screen with a library from human testis and the catalytic a-and a 0 -subunits of protein kinase CK2 as a bait, we found several interacting partners whose DNA was subsequently sequenced. Two clones out of 20 corresponded to nucleotides 873-1092 (amino acids 291-360) of the human splicing factor hPrp3p. The positive interaction of one of these clones with both catalytic subunits (4 and 5) in yeast is shown in Figure 1 . Control experiments with empty vectors and with CK2a and CK2a 0 constructs together with empty vectors were all negative.
To verify the interaction, hPrp3p was in vitro translated and labelled with 35 S-methionine, and the CK2 holoenzyme and catalytic a-subunits were bacterially expressed and purified according to standard protocols (Guerra et al., 1998) . The CK2 subunits or the holoenzyme were mixed with the in vitro translated hPrp3p and incubated for 2-3 h. An interaction between these proteins was analysed by coimmunoprecipitation experiments. Immunoprecipitation was performed with an antibody against the Xpress-tag of recombinant hPrp3p. After sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by a western blot analysis, CK2 was detected with specific antisera. As shown in Figure 2 hPrp3p coimmunoprecipated with the catalytic subunits of CK2 (Figure 2a, lane 3) but not with the CK2 holoenzyme consisting of catalytic a-and regulatory b-subunits (Figure 2b, lane 2) . These results showed that hPrp3p indeed bound to the catalytic a-and a 0 -subunits of CK2 but it failed to bind to the CK2 holoenzyme.
For further analyses we generated a polyclonal serum in rabbits (no. 771) against amino acids 608-618 of hPrp3p as schematically shown in Figure 3a . The serum was characterized by western blot analysis, immunoprecipitation and immunofluorescence. The antiserum was able to recognize a protein of about 90 kDa and its degradation products in HeLa cell extract ( Figure 3b ). As shown in Figure 3c it is also able to immunoprecipitate the hPrp3p protein from HeLa cell extract whereas the preimmune serum did not detect a corresponding protein. Furthermore, immunofluorescence analysis revealed that it detects the protein in nuclear speckles of HeLa cells ( Figure 3D , a-c). The antigen-antibody interaction was successfully competed by the addition of increasing amounts of the peptide used for immunization. Thus, the antiserum was suitable for the following in vitro and in vivo experiments.
In a next experiment we analysed the interaction of CK2a and hPrp3p in mammalian cells. We used human (2) pGBKT7-CK2a and parental pAct2, (3) pGBKT7-CK2 a 0 and parental pAct2, (4) pGBKT7-CK2a and pAct2-hPrp3p (nt 873-1092), (5) pGBKT7-CK2a 0 and pAct2-hPrp3p (nt 873-1092).
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CK2β Figure 2 Co-immunoprecipitation of recombinant CK2 and hPrp3p. (a) hPrp3p was in vitro translated and incubated either with the recombinant CK2a-or CK2a 0 -subunit. hPrp3p was immunoprecipitated with an antibody, which was directed against the Xpress-tag of hPrp3p and 35 S-labelled hPrp3p was detected by fluorography. CK2 subunits were detected in a western blot analysis with specific sera. Lane 1: input control; lane 2: control immunoprecipitation without hPrp3p; lane 3: immunoprecipitation with hPrp3p. (b) hPrp3p was in vitro translated and incubated with recombinant CK2 holoenzyme. hPrp3p was immunoprecipitated with an antibody directed against its tag. CK2a-and CK2b-subunits were detected with specific sera in a western blot analysis. Lane 1: control immunoprecipitation without hPrp3p; lane 2: immunoprecipitation with hPrp3p and CK2 holoenzyme; lane 3: input control.
CK2 is implicated in RNA splicing S Lehnert et al HeLa cells that turned out to have detectable amounts of hPrp3p. Cells were synchronized with hydroxyurea and hPrp3p immunoprecipitated from cell extracts of G 1 -, S-and G 2 /M-phase cells using serum 771. Figure 4a shows the cytofluorimetry analysis of the synchronized cells, which demonstrates that we indeed used G 1 -, S-and G 2 /M-phase cells. According to SDS-PAGE and western blot analysis, hPrp3p and the CK2a-subunit were present in all cell extracts (Figure 4b , lane 4) throughout the cell cycle in similar amounts. However, we only succeeded in coimmunoprecipitating detectable amounts of the CK2a-subunit from cell extracts of both gap phases (Figure 4 , lane 2). Lane 1 shows control precipitates without serum 771, lane 3 shows an aliquot of the supernatant after the immunoprecipitation demonstrating that only a fraction of CK2a was coimmunoprecipitated. Thus, we have to conclude that the interaction between the catalytic subunit of CK2 and hPrp3p exists in vivo, but only during the gap phases of the cell cycle.
To show the interaction in vivo by another method we subjected synchronized HeLa cells to an immunofluorescence study with hPrp3p-specific and CK2a-specific antibodies ( Figure 5 ). In cells from all cell cycle phases hPrp3p was predominantly found in nuclear speckles, which is a typical distribution for splicing factors. In contrast, CK2a was found all over the nucleus and somewhat weaker in the cytosol. When merging the two pictures we observed a strong colocalization of both proteins during the gap phases of the cell cycle showing the strongest signals during the G 1 phase. Thus, this data supports the results of the coimmunoprecipitation analysis and confirmed the cell-cycle-dependent interaction between the catalytic a-subunit of CK2 and hPrp3p.
hPrp3p is phosphorylated by the CK2 holoenzyme So far, we have shown that hPrp3p is a binding partner of the CK2a-and a 0 -subunits but not of the holoenzyme. In order to test whether hPrp3p is a phosphoprotein HeLa cells were labelled with 33 P-orthophosphoric acid for 4 h. Cells were harvested and proteins subjected to an immunoprecipitation using the hPrp3p-specific antiserum 771. After SDS-PAGE and autoradiography of the immunoprecipitated proteins hPrp3p was detected as a phosphoprotein ( Figure 6 , lane 2). In the next step we analysed whether phosphorylation of hPrp3p is due to CK2. Thus, in a parallel experiment we treated cells with the CK2 inhibitor tetrabromobenzotriazole (TBB) during labelling. Figure 6 (lane 3) clearly demonstrates that the phosphorylation of hPrp3p was strongly reduced by this treatment. Therefore, we demonstrated that hPrp3p is a phosphoprotein in vivo and that the phosphorylation is probably done by protein kinase CK2. The following in vitro experiments served to further characterize the phosphorylation.
As the CK2 holoenzyme, consisting of catalytic and regulatory subunits, as well as the individual a-subunits CK2 is implicated in RNA splicing S Lehnert et al are known to phosphorylate proteins, we performed in vitro phosphorylation assays with both enzymes. hPrp3p was expressed as His-tagged protein in bacterial cells and purified by affinity chromatography with a Ni 2 þ -NTA chelate resin. The purified hPrp3p was used for the phosphorylation with CK2. In Figure 7a (lane 2) we show that hPrp3p is phosphorylated by the CK2 holoenzyme. Time course studies of the phosphorylation ( Figure 7b ) revealed that at the latest after 30 min the hPrp3p protein was saturated with phosphate. Thus, we chose this time point to determine the phosphate incorporation into hPrp3p by CK2. We performed six independent experiments and determined the incorporation rate to be 0.39 ± 0.09 mol phosphate into 1 mol of hPrp3p. In order to compare the rate of phosphate incorporated in hPrp3p with a well-known and excellent Immunofluorescence analysis of hPrp3p and CK2a in synchronized Hela cells. HeLa cells were synchronized using hydroxyurea. Cells of the corresponding cell cycle phases were fixed with formaldehyde and permeabilized with Triton-X100. Cells were stained with antibodies against hPrp3p (771) or CK2a (1A5) and the corresponding FITC-or TRITC-labelled secondary antibodies. Magnification: 400 Â .
CK2 is implicated in RNA splicing S Lehnert et al substrate of CK2 we used a C-terminal fragment of nucleolin (amino acids 269-710) (Schneider and Issinger, 1988) . In this case we found an incorporation rate of 2 mol phosphate into 1 mol of the nucleolin fragment (not shown). Thus, in comparison to nucleolin hPrp3p seems to be a poor substrate. As hPrp3p obviously binds to the catalytic subunits of CK2 independently of the regulatory b-subunit we were interested if the a-subunit is also able to phosphorylate the protein. However, the catalytic a-subunit alone was unable to phosphorylate hPrp3p (Figure 7a , lane 3 and 4) although the enzyme phosphorylated the CK2a substrate mdm2 (Guerra et al., 1997) (Figure 7a , lane 5). Next, we wanted to map the phosphorylation site on the polypeptide chain of hPrp3p. We started to subclone three fragments of hPrp3p (H1-H3) into bacterial expression vectors, then expressed and purified the protein fragments. Figure 7c shows the result of the phosphorylation by the CK2 holoenzyme. The N-terminal and the middle fragment were not or only weakly phosphorylated (lane 1 and 2). In contrast, the C-terminal fragment (amino acids 457-682) was significantly phosphorylated (Figure 7c, lane 3) . This C-terminal fragment harbours six out of thirteen consensus sequences of hPrp3p for CK2. Therefore, we have to conclude that hPrp3p is predominantly phosphorylated at one or several sites within the C-terminus. Figure 7d shows a western blot analysis of aliquots of the hPrp3p fragments with an antibody against the His-tag.
In order to narrow down the phosphorylation site more exactly we further used a peptide library containing all the putative CK2 phosphorylation sites. The peptides consist of 11 amino acids with the serine or threonine to be phosphorylated in the middle of the sequence (bold letters in the table of Figure 8 ). The peptide library was incubated with CK2 and 32 PgATP; Figure 8 shows the result of the autoradiography. We reproducibly observed several spots which were present in the library but not in the control experiment without CK2. These spots represent peptides containing serine or threonine residues S81 (peptide 2), T452 (peptide 7), S619 (peptide 10) and S642 (peptide 12). Besides the serine residue at position 81, which was only weakly phosphorylated, and threonine 452, the other sites are located in the C-terminal fragment of hPrp3p (see Figure 7 ). The splicing activity of the spliceosome is influenced by the CK2/hPrp3p interaction Next, we analysed the functional consequences of the interaction between the catalytic a-and a 0 -subunits of CK2 and hPrp3p. hPrp3p is a splicing factor involved in the processing of pre-mRNA. Whereby, we asked if the splicing activity of hPrp3p is somehow compromised by the interaction with CK2a. We treated HeLa cells with the CK2 inhibitor TBB and analysed the effect on the splicing activity of the nuclear extract. By the application of 25 or 50 mM TBB the activity of CK2 was downregulated to 40 or 20% of the original activity, respectively (Figure 9a ). The expression of the catalytic a-subunit remained the same during the treatment ( Figure 9b ). As pre-mRNA for the splicing assay we used an E1A minigene which is under normal conditions spliced to a 13S, 12S, 10S and 9S mRNA (Figure 9c , (0) and Figure 9d ). In the presence of TBB (50 mM) the splicing pattern is changed in favour of the unspliced form of the pre-mRNA. Thus, the inhibition of protein kinase CK2 obviously compromises the splicing process.
In another approach to specifically target protein kinase CK2 we downregulated the CK2 kinase activity by the application of kinase-dead dominant negative mutants CK2a K68M and CK2a 0 K69M (Penner et al., 1997) . We transfected HeLa cells with these two mutants. In order to enhance the amount of CK2 we transfected HeLa cells with wild-type CK2a or CK2a 0 cDNAs. HeLa cells transfected with the parental pRc/CMV vector served as control. We harvested the cells 72 h after the transfection. As shown in Figure 10a the exogenous CK2 subunits were detected in a western blot analysis. The kinase activity of CK2 was enhanced up to 120% when expressing the two a-subunits; by transfecting the kinase dead CK2a-or CKa 0 -subunit the CK2 activity was reduced to 40 or 55%, respectively (Figure 10b ).
We used the nuclear extracts of transfected and control cells to perform a splicing assay as described (0) cells and cells treated with 25 or 50 mM TBB using specific sera for CK2a and GAPDH. (c) mRNA was isolated from HeLa cells that were either left untreated (0) or treated with TBB and subjected to a reverse transcriptase reaction. E1A cDNA was amplified with specific primers and analysed by agarose gel electrophoresis in a 2.5% agarose gel. After staining with ethidium bromide the different E1A splicing products were visualized. (d) Schematic drawing of the full length RNA and the different splice products.
CK2 is implicated in RNA splicing S Lehnert et al above. Figure 11 presents the results of the splicing assay. Compared to the control (À) the splicing pattern changed by the overexpression of CK2 in different ways. By the overexpression of the CK2a-subunits, which enhance the kinase activity in the cell, the amount of the spliced forms increased; thus, the splicing activity of the spliceosome is activated. This is even more pronounced in the presence of the CK2a 0 -subunit (Figure 11a) . By transfecting the kinase-dead mutants of CK2 ( Figure  11b ) the activity of the spliceosome is reduced compared to the control. The splicing pattern is changed in favour of the unspliced form, which is especially observed in the presence of the kinase-dead CK2a-subunit.
Therefore, we have to conclude that the kinase activity of CK2 influences the splicing capacity of the spliceosome. Moreover, both catalytic subunits obviously play different roles in the regulation of the splicing process.
Discussion
In the present study we identified a new binding partner for the catalytic a-and a 0 -subunits of protein kinase CK2 namely hPrp3p. Moreover, in addition to being a binding partner, hPrp3p is also a substrate for the CK2 holoenzyme consisting of two regulatory and two catalytic a-or a 0 subunits, but not for the catalytic subunits alone. Binding partners for the individual subunits of CK2 were already detected earlier including hsp90, PP2a, Pim-1, CKIP-1, cyclin H, NAP1 and Egr-1 (Jain et al., 1996; Li et al., 1999; Bosc et al., 2000; Faust et al., 2002; Messenger et al., 2002) . Some of these binding partners are also substrates for the CK2 kinase. Regarding the function, hPrp3p is a new type of binding partner, because it does not belong to the class of proteins involved in cellular signalling, cell cycle control or intracellular trafficking, instead hPrp3p is implicated in splicing. Together with hPrp4p hPrp3p is associated with the U4/U6 small nuclear ribonucleoprotein particle, which is essential for the assembly of an active spliceosome (Gonzalez-Santos et al., 2002) . These snRNAs recognize conserved sequences of the premRNA and assemble into a catalytically active spliceosome that catalyses the cleavage/ligation reactions of RNA splicing. Mapping the binding site for the 
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S Lehnert et al interaction between hPrp3p and hPrp4p revealed that the interaction domain resides in the central region of hPrp3p, within the same region that was found to be responsible for its interaction with CK2a or CK2a 0 in the two-hybrid screen. hPrp3p has an RNA binding activity at least in vitro and it is believed that it assembles proteins like hPrp4p as well as snRNAs at the spliceosome. Thus, one might speculate that CK2 is targeted to the spliceosome by its interaction with hPrp3p. This assumption is further supported by the finding that the RNA binding site seems to be located within the C-terminus of hPrp3p, which is distinct from the CK2a and a 0 binding site. As shown by 33 P-phosphate labelling of cells hPrp3p is a phosphoprotein. Phosphorylation of hPrp3p is at least partially inhibited by treating the cells with TBB a specific inhibitor of protein kinase CK2 (Sarno et al., 2001) . Furthermore, bacterially expressed hPrp3p was readily phosphorylated by CK2 in vitro. Incorporation analysis revealed that 0.4 mol phosphate were incorporated into 1 mol hPrp3p protein which means that about 40% of hPrp3p is phosphorylated by CK2. In comparison to hPrp3p, nucleolin is a better substrate that incorporated 2 mol phosphate per mol protein. The use of different fragments of hPrp3p indicated that the C-terminus of hPrp3p seems to harbour the main phosphorylation site(s). This initial result was confirmed by a peptide filter assay which revealed that two different sites in the C-terminus, one in the middle part and one in the N-terminal part can be phosphorylated by CK2.
Although hPrp3p is associated with CK2a it is not a substrate for the catalytic subunit alone. A prototype of a CK2a substrate is calmodulin, which is not phosphorylated by the holoenzyme (Meggio et al., 1994) . Instead hPrp3p is readily phosphorylated by the CK2 holoenzyme. Thus, binding of the a-subunit has a function, which is clearly different from the interaction with the holoenzyme. One might speculate that hPrp3p targets the CK2a subunit to the spliceosome where it may phosphorylate other substrates.
RNSP1, which was originally described as a premRNA splicing activator and which is a component of an active spliceosome is bound by CK2a. Furthermore, it is phosphorylated at serine 53 (Trembley et al., 2005) by CK2 at least in vitro. This phosphorylation stimulated the splicing activity of RNPS1. Similar to RNSP1, here we showed that an inhibition of the hPrp3p phosphorylation also leads to an inhibition of the splicing. Several proteins, which are implicated in transcription and posttranscriptional processes are substrates for protein kinase CK2 including RNA polymerase II (Payne et al., 1989) , cyclin H (Schneider et al., 2002) and FCP1 (TFIIF-dependent CTD phosphatase) (Trembley et al., 2003) . Interestingly, RNPS1 also interacts with the largest subunit of RNA polymerase II. It was shown that the phosphorylation of the CTD of RNA polymerase also plays a role in posttranscriptional mRNA processing (Proudfoot et al., 2002) . The RNA polymerase multiprotein complex also harbours cdk11, which is a cyclin-dependent kinase.
However, this kinase does not phosphorylate the CTD of RNA polymerase II. But there was a kinase activity associated with cdk11, which later on turned out to be protein kinase CK2 (Trembley et al., 2003) . Thus, this data together with the data presented here show that CK2 plays an important role in the regulation of transcription and posttranscriptional processes. Here, we add a particular role in RNA splicing.
Material and methods

Yeast-two-hybrid analysis
Yeast-two-hybrid screens against CK2a and CK2a 0 were performed using the Matchmaker-System from Clontech according to the manufacturer's instructions. Plasmids used for the screens were pGBKT7 that contained the respective CK2-subunits and a human testis cDNA library subcloned into pACT2. Transformed yeast cells were grown on single dropout media missing both leucine and tryptophan only or leucine, tryptophan, histidine and adenine. Individual clones were sequenced and identified by a database search.
In vitro translation hPrp3p was subcloned into the pRSET A plasmid containing an N-terminal Xpress-tag (Invitrogen, Karlsruhe GmbH, Germany). In vitro transcription was performed using the 'TNT T7 coupled reticulocyte lysate system' (Promega GmbH, Mannheim, Germany) according to the manufacturer's protocol.
Cell culture and in vivo labelling of cells with 33 P-orthophosphoric acid HeLa and cos 1 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS). Cells were grown to 75% confluence in 10 cm dishes in a 5% CO 2 atmosphere.
For in vivo labelling of proteins with 33 P-orthophosphoric acid subconfluent cells were washed three times with phosphate free DMEM and subsequently incubated with this medium for 30 min at 37 1C. After this time 33 P-orthophosphoric acid (100 mCi in 1 ml medium) was added to the cells and labelling of the proteins was performed for 2 h. After this time cells were washed three times with ice cold PBS and harvested.
Synchronization of cells and cytofluorimetry
Subconfluent asynchronous HeLa cells were treated with 4 mM hydroxyurea at 37 1C for 24 h and were thus blocked at the G 1 / S transition of the cell cycle. After removal of hydroxyurea, cells reentered the cell cycle as a synchronous population for 1-2 complete cell cycles. After 30 min, 4 and 8 h cells were harvested as G 1 , S and G 2 /M population, respectively. An aliquot of the cells was subjected to a cytofluorimetry analysis.
For cytofluorimetry analysis cells were detached from the culture dish by using a trypsin/EDTA solution in PBS and transferred to a centrifuge tube. Cells were sedimented at 400 Â g and the pellet was resuspended in 200 ml PBS. Cells were fixed by adding vigorously 2 ml ice-cold 70% ethanol and incubation at À20 1C for 30 min. The cell suspension was centrifuged at 400 Â g and the sediment was resuspended in 800 ml PBS. Finally, cells were treated with 100 ml RNase A (1 mg ml
À1
) and 100 ml propidium iodide (400 mg ml
) to stain the nuclei. Cells were analysed using a FACScan II cytofluorimeter (excitation: 488 nm, emission: 630 nm) and the CellQuest software from Becton Dickinson.
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Preparation of cell extracts
Cells were harvested, washed 3 Â with phosphate buffered saline (PBS), pH 7.4, and resuspended in lysis buffer (100 mM Tris-HCl, pH 9.0, 100 mM NaCl, 0.5% (v/v) NP40, 1% Trasylol). Proteins were extracted for 1 h on ice. Cell debris was eliminated by centrifugation (4 1C, 30 min, 13.000 Â g).
Antibodies and western blot analysis
For the detection of protein kinase CK2 we used polyclonal sera 26 (a-subunit), 30 (a 0 -subunit) and 269 (b-subunit) (Faust et al., 1999; Go¨tz et al., 2005) . Polyclonal rabbit serum 771 was raised against a peptide corresponding to amino acids 608-618 (CTSNTKGDDDEE) of the hPrp3p protein. Alternatively, we used the commercially available antibody 4E3 from Biozol Diagnostica, Eching, Germany. For the detection of GAPDH as housekeeping protein we used a polyclonal serum (Santa Cruz, Heidelberg, Germany). In vitro translated hPrp3p was detected using the mouse monoclonal Xpress-tag antibody SK2. The preparation of cell extracts, SDS-PAGE, and blotting procedure were described earlier . For detection we used the Lumilight system (Roche Diagnostics).
Immunofluorescence Cells were grown on coverslips until they were 50-70% confluent. Cells were fixed in 2% formaldehyde in PBS, pH 7.4, for 15 min at 20 1C and then washed with PBS, pH 7.4, for 3 Â 10 min. Cells were permeabilized with 0.5% Triton X-100. Cells were washed again with PBS three times for 10 min and then blocked with PBS containing 10% bovine serum albumin (BSA), then incubated with a primary antibody in the appropriate concentration for 1 h at room temperature in a humidified chamber. Cells were washed and then incubated with the secondary antibody (FITC-or TRITC-conjugated) at room temperature for 1 h in a dark, humidified chamber. Finally, cells were washed again with PBS (4 Â 10 min). The coverslips were fixed with a drop of mounting media and analysed under a fluorescence microscope.
Immunoprecipitation
For immunoprecipitation we used the polyclonal hPrp3p-serum (serum 771) and a monoclonal CK2a antibody (1A5). A protein A/G-sepharose mixture was preincubated for 1 h with 30 ml of the serum or with 10 ml (1 mg ml À1 ) of the monoclonal anti-CK2a antibody and washed three times with PBS, pH 7.4. Four milligrams cell extract or 10 mg purified proteins was preincubated with a mixture of protein A-and protein G-sepharose to remove unspecifically bound proteins. The supernatant was applied to the preincubated sepharoseantibody matrix and incubated for 1 h. The supernatant was removed and the antibody-matrix washed five times with RIPA buffer (50 mM Tris/HCl, pH 8.0, 150 mM NaCl, 0.5% sodium deoxycholate, 1% Triton X-100, 0.1% sodium dodecyl sulfate). The immune complex was subjected to SDS-PAGE, followed by western blotting.
Purification of CK2 holoenzyme
Recombinant CK2 holoenzyme cloned in a bicistronic vector (Shi et al., 1994) and the three different subunits (a, a 0 and b in pT7-7) of the protein kinase CK2 were expressed in Escherichia coli BL21 (DE3) and the proteins were purified according to a protocol published by Grankowski et al. (1991) . The bacterial pellet was lysed and after incubation on ice for 10 min, the lysate was sonicated two times and centrifuged (10 000 Â g, step 1). The pellet was resuspended in buffer P1500 (20 mM Tris-HCl, pH 8.0, 7 mM 2-mercaptoethanol, 1 mM phenylmethyl sulfonylchloride (PMSF) and 1.5 M NaCl). Proteins were extracted overnight, pooled with the supernatant from the first step, and dialysed against buffer P300 (20 mM Tris-HCl, pH 8.0, 7 mM 2-mercaptoethanol, 1 mM PMSF and 300 mM NaCl). The lysate was loaded onto a P11 column preequilibrated with buffer P300 and eluted with a linear gradient from 0.3 to 1.5 M NaCl. Fractions containing active holoenzyme were dialysed against buffer P300, concentrated and loaded onto a Superose-6 column (Pharmacia, GE Healthcare, Freiburg, Germany). After gel filtration the peak fractions were collected.
Expression and purification of bacterially expressed proteins Full-length hPrp3p, an N-terminal (amino acids 1-228), a middle (amino acids 229-456) and a C-terminal fragment (amino acids 457-682) of hPrp3p were subcloned into bacterial expression plasmid pQE30 containing an N-terminal histidinetag, transformed into E. coli strain M15. Clones were incubated overnight in 50 ml LB-medium. One litter LB-medium was inoculated with the overnight-culture, grown to early log phase and induced with 1 mM isopropyl-b-D-thiogalactoside at 30 1C for 6 h. Cells were harvested by centrifugation and resuspended in 6 M guanidine hydrochloride, 0.1 M sodium phosphate, pH 8.0 and lysed at 4 1C overnight. The lysate was cleared by centrifugation and loaded onto a prewashed Ni 2 þ -chelate agarose column and incubated for 1 h at room temperature. The column was washed with 10 volumes of lysis buffer, followed by 10 volumes of lysis buffer, pH 6.0, and lysis buffer, pH 8.0 containing 20 mM imidazole. Proteins were eluted with lysis buffer containing 300 mM imidazole and subsequently dialysed overnight against dialysis buffer A (20 mM Tris-HCl, pH 7.5, 100 mM KCl, 5 mM MgCl 2 , 0.1% Tween 20).
In vitro phosphorylation
To analyse the CK2 activity in cell extracts 30 mg of the protein extracts were mixed with kinase buffer (50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 10 mM MgCl 2 , 1 mM DTT) to a total volume of 20 ml and incubated with the synthetic peptide RRRDDDSDDD (Kuenzel and Krebs, 1985) by adding 30 ml assay buffer (25 mM Tris-HCl, pH 8.5, 150 mM NaCl, 5 mM MgCl 2 , 1mM DTT, 50 mM ATP, 0.19 mM substrate peptide, 10 mCi 32 PgATP/500 ml). The phosphorylation reaction was allowed to take place for 5 min at 37 1C. The mix was spotted onto a P81 ion exchange paper and washed three times with 85 mM H 3 PO 4 . After treatment with ethanol the paper was dried, and incorporated radioactivity was determined in a scintillation counter.
For the analysis of the phosphorylation of hPrp3p recombinant hPrp3p proteins were mixed with recombinant protein kinase CK2 in 20 ml kinase buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM MgCl 2 , 1 mM DTT). The phosphorylation reaction was started by the addition of 32 PgATP. For studying the phosphate incorporation we used 50 mM ). After 30 min at 37 1C the reaction was stopped by the addition of 10 ml sample buffer. Proteins were separated in an SDS polyacrylamide gel and visualized by autoradiography. The incorporated radioactivity was measured from the excised bands by scintillation counting.
Undecapeptides representing the putative CK2 phosphorylation sites of the hPrp3p sequence were synthesized and immobilized on a cellulose membrane according to the Spot's method with a partially automated synthesizer (Abimed AutoSpot Robot ASP 222) as recommended by the manufacturer (Abimed GmbH, Langenfeld, Germany). The membrane was equilibrated overnight in kinase buffer supplemented with 1% BSA. For phosphorylation of the peptides the membrane was incubated in 2 ml kinase buffer with recombinant CK2 in the PgATP. After 30 min at 37 1C the membrane was washed three times with 1 M NaCl and subsequently with a urea-containing buffer (8 M urea, 1% sodium dodecyl sulfate, 0.5% 2-mercaptoethanol) to remove any bound proteins. Finally, the membrane was washed with ethanol and dried. Phosphorylated peptides were visualized by autoradiography.
Inhibition of protein kinase CK2
The activity of protein kinase CK2 in vivo was inhibited by the specific inhibitor TBB. TBB was added to the cell-culture medium in concentrations of 25 or 50 mM.
In vivo splicing-assay In vivo splicing-assays were performed according to Maita et al. (2004) . Briefly, an adenovirus E1A reporter plasmid pCMV-E1A was transfected into HeLa cells. After transfection cells were either treated with TBB or transfected with the kinase dead CK2a-or a 0 -constructs (Penner et al., 1997) . Forty-eight hours after transfection of the reporter plasmid total RNAs were extracted and subjected to a Reverse transcription-PCR reaction using exon 1-and 2-primers. PCR products were then analysed on a 2.5% agarose gel.
